Gastrointestinal Cancer | Topics

 
First-Line Tremelimumab ± Durvalumab Misses ORR End Point in Biliary Tract Cancer
September 30, 2022

Results from the phase 2 IMMUCHEC trial indicated that tremelimumab with or without durvalumab did not meet the primary end point of improved objective response rate vs chemotherapy in patients with treatment-naïve biliary tract cancer.

GNS561 Granted Orphan Drug Designation by FDA in Second-Line Cholangiocarcinoma
September 20, 2022

The FDA has granted orphan drug designation to second-line GNS561 following the completion of a phase 1/2a trial evaluating the novel PPT1 inhibitor in liver cancer and cholangiocarcinoma.

RLY-4008 Demonstrates Promising Activity in FGFR2-Positive Cholangiocarcinoma
September 12, 2022

Findings from the phase 1/2 ReFocus study highlighted that RLY-4008 is a potentially transformative agent for the treatment of FGFR inhibitor–naïve, FGFR-mutant cholangiocarcinoma.

Clinical Benefit of Trastuzumab Deruxtecan Sustained in Metastatic Gastric/GEJ Cancer
September 10, 2022

Long-term follow-up of the phase 2 DESTINY-Gastric02 study revealed fam-trastuzumab deruxtecan-nxki continues to show promise in locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

Durvalumab Plus Chemo Receives FDA Approval in Locally Advanced/Metastatic Biliary Tract Cancer
September 02, 2022

Patients with locally advanced or metastatic biliary tract cancer can now receive treatment with durvalumab plus gemcitabine following the combination’s approval by the FDA.

Weijing Sun, MD, FACP, Reviews Trends in Gastrointestinal Cancer
August 17, 2022

“...we don’t focus on survivorship enough. It’s important to understand the other factors involved in surviving besides just a treatment.”

FOLFOX Plus Trastuzumab and Nivolumab Demonstrated Promising Efficacy in ERBB2+ Esophagogastric Adenocarcinoma
July 19, 2022

Patients with ERBB2-positive esophagogastric adenocarcinoma appeared to experience improved efficacy following treatment with a combination of trastuzumab and nivolumab plus leucovorin, fluorouracil, and oxaliplatin vs historical data.

A Pilot Study of Omalizumab to Treat Oxaliplatin-Induced Hypersensitivity Reaction
July 18, 2022

Stacy Stein, MD, and co-investigators, research omalizumab to treat oxaliplatin hypersensitivity reactions for patients with gastrointestinal cancers.

FDA Delays Decision of Tislelizumab Monotherapy for Previously Treated Unresectable Advanced or Metastatic ESCC
July 14, 2022

The FDA has delayed the decision to approve tislelizumab monotherapy for patients with advanced or metastatic esophageal squamous cell carcinoma following prior systemic therapy, due to COVID-19 travel restrictions.

Howard A. Burris, MD, Talks QOL With Durvalumab/Chemo in Advanced Biliary Tract Cancer From TOPAZ-1 Trial
July 13, 2022

Howard A. Burris, MD, highlighted previous findings of the phase 3 TOPAZ-1 trial assessing durvalumab plus gemcitabine and cisplatin vs placebo plus gemcitabine and cisplatin in advanced biliary tract cancer and patient-reported outcomes data that were presented at 2022 ASCO.